| Bioactivity | Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2]. |
| Invitro | Cantuzumab ravtansine（huC242-DM4；5 天）在 CanAg 阳性 SNU16 胃癌细胞中表现出细胞毒性作用[2]。 |
| In Vivo | Cantuzumab ravtansine（huC242-DM4；静脉注射；3.4 mg/kg；单剂量）可使携带 N87 人胃肿瘤异种移植物的 SCID 小鼠的肿瘤完全消退，在低于 2 mg/kg 的剂量下观察到显着的肿瘤消退 [1]。Cantuzumab ravtansine (huC242-DM4) 在携带人结肠肿瘤异种移植物 HT29 和 COLO 205 细胞的小鼠中也有疗效，且无毒副作用[1]。 |
| Name | Cantuzumab ravtansine |
| CAS | 868747-45-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Robert J. Lutz, et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. Cancer Res (2005) 65 (9_Supplement): 334-335. [2]. Olga Ab, et al. Activity of huC242-DM4, an antibody-cytotoxic agent conjugate, used in combination with anti-neoplastic agents against gastric cancer cells in culture. Mol Cancer Ther (2007) 6 (11_Supplement): A127. |